A phase 3, randomized, open-label study of NKTR-214 combined with nivolumab versus nivolumab in particpants with previously untreated unresectable or metastatic melanoma
To compare ORR, PFS and OS of NKTR-214 combined with nivolumab and that of nivolumab monotherapy in participants with previously untreated unresectable or metastatic melanoma
nivolumab + NKTR vs nivolumab alleen (1:1 randomisatie)
nivolumab + NKTR vs nivolumab alleen (1:1 randomisatie)
Karijn Suijkerbuijk en Annemarleen Kamphuis